

55. (Amended) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:  
implanting a vascular prosthesis in the blood vessel; and  
releasing methylprednisolone and at least one other substance in addition to methylprednisolone from the prosthesis when implanted in the blood vessel, wherein the immunosuppressive substance is mizoribine.

*B2*  
56. (Amended) A method for inhibiting restenosis in a blood vessel following recanalization of the blood vessel, said method comprising:  
implanting a vascular prosthesis in the blood vessel; and  
releasing methylprednisolone and at least one other substance in addition to methylprednisolone from the prosthesis when implanted in the blood vessel, wherein methylprednisolone is released within a time period of 2 days to 3 months.

*B3*  
61. (New) A method as in claim 55, wherein methylprednisolone is released within a time period of 2 days to 3 months and mizoribine is released within a time period of 1 day to 45 days.

REMARKS

In the Office Action, the Examiner noted that: Claims 1-60 are pending in the application, of which Claims 1-36 are withdrawn from consideration; Claims 37-54 and 57-60 are rejected; and Claims 55-56 are objected to.

As of the present amendment, Claims 1-60 are pending in the application of which Claims 1-36 are withdrawn from consideration, and Claims 37-60 are under consideration.

Response to Office Action Paragraph 2 Objection to Specification

In the Office Action the disclosure was objected to because of informalities, namely, blank spaces on page 3 lines 18-21 which appear to be missing some information.